Skip to main content
. 2021 Jul 8;12:677957. doi: 10.3389/fimmu.2021.677957

Table 1.

Baseline characteristics of cohort studies included.

First Author Publication Date Country Sample size Disease Type Intervention Antibiotic Outcomes Factors for Multivariate Analysis
Mariangela Allocca (19) 2020 Oct Italy 41 29%UC, 22%CD, 20%PS, 10%PsA, 12%RA, 2%AS, 2%SSc, 2%SLE,1%others 7CS, 10IM, 28BIO NA hospitalizaiton, oxygen need, death, age, gender, medication, comorbidities, rheumatic disease diagnosis
Milena Gianfrancesco (20) 2020 May Multi-national 600 38%RA, 14%SLE, 12%PsA, 8%AS, 7%vasculitis, 5%SS, 3%SSc, 10%others 32CS NA hospitalizaiton, death, age, gender, rheumatic disease diagnosis, comorbidities, medication
Anja Strangfeld (21) 2021 Jan Multi-national 3279 36.7%RA, 12.5%AS, 12.6%PsA, 10.6%SLE, 7.7%vasculitis, 19.9%others 1056CS, 1267DMARD, 296IM, 1310BIO NA death age, gender, rheumatic disease diagnosis, comorbidities, medication
FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (22) 2021 Apr France 694 30.7%RA, 23.8%AS, 10.1%PsA, 9.3%vasculitis,6.6%SLE, 3.6%SSc, 2.5%SS, 13.5%others 215CS, 328IM,354BIO NA moderate:hospitalization, severe:ICU or death age, gender, diagnosis, medications, comorbidities
Jesse Veenstra (23) 2020 Dec USA 77 33.8%RA/AS, 13.6%PS/PsA, 17.8%IBD, 15.5%SLE/DM/PM/MCTD/ILD/Scl 12CS, 41IM, 30BIO NA hospitalization,ventilator NA
Rebecca Haberman (24)  2020 Apr USA 86 16%PS, 24%PsA, 23%RA, 20%UC, 23%CD, 10%AS 62BIO,17MTX, 8CS NA hospitalizaiton, oxygen need, ICU, death, age,sex,comorbidities,BMI,medication
Mariangela Allocca (25) 2020 Nov Multi-national 97 44%UC,55%CD, 1% IBD-U 8CS,24IM,51BIO, NA hospitalization, ICU, death age, gender, comorbidities, diagnosis, medication
Claudia Diniz Lopes Marques (26) 2021 Jan Brasil 334 32.9%SLE, 28.4%RA, 13.5%AS, 6.9%SSc, 6.9%PsA, 3.3%vasculitis, 8.3%others 234CS, 154IM,116BIO NA hospitalization, ICU, ventilation, death age, diagnosis, medication, comorbidities

UC, ulcerative colitis; CD, Crohn’s disease; IBD-U, inflammatory bowel disease-unclassified; PS, psoriasis; PsA psoriatic arthritis; RA, rheumatoid arthritis; AS, ankylosing spondylitis; SLE, Systemic lupus erythematosus; SS, Sjogren’s syndrome; SSc, systemic sclerosis; DM, dermatomyositis; PM, polymyositis; MCTD, mixed connective tissue disease; ILD, interstitial lung disease; CS, corticosteroids; IM, immunocmodulators; BIO, biologics; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate.